DAWN
Day One Biopharmaceuticals, Inc. Healthcare - Biotechnology Investor Relations →
Day One Biopharmaceuticals, Inc. (DAWN) closed at $21.44 as of 2026-03-20, trading 58.0% above its 200-week moving average of $13.57. The stock moved further from the line this week, up from 57.9% last week. With a 14-week RSI of 86, DAWN is in overbought territory.
Over the past 14 weeks, up-weeks have carried more volume than down-weeks (3.07 buyers-vs-sellers ratio). When trading picks up, it's more often on days the price is rising — buyers are showing more interest than sellers.
Over the past 203 weeks of data, DAWN has crossed below its 200-week moving average 3 times. On average, these episodes lasted 55 weeks. Historically, investors who bought DAWN at the start of these episodes saw an average one-year return of +7.9%.
With a market cap of $2.2 billion, DAWN is a mid-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -22.7%. The stock trades at 5.0x book value.
Share count has increased 40.2% over three years, indicating dilution.
Over the past 3.9 years, a hypothetical investment of $100 in DAWN would have grown to $305, compared to $166 for the S&P 500. That represents an annualized return of 33.0% vs 13.8% for the index — confirming DAWN as a market-beating investment and the kind of quality company where buying during 200-week moving average touches has historically been rewarded.
Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: DAWN vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After DAWN Crosses Below the Line?
Across 3 historical episodes, buying DAWN when it crossed below its 200-week moving average produced an average return of +20.7% after 12 months (median -7.0%), compared to +15.3% for the S&P 500 over the same periods. 33% of those episodes were profitable after one year. After 24 months, the average return was +6.0% vs +41.3% for the index.
Each line shows $100 invested at the moment DAWN crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
DAWN has crossed below its 200-week MA 3 times with an average 1-year return of +7.9% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| May 2022 | Jun 2022 | 7 | 68.1% | +62.9% | +155.2% |
| Jul 2022 | Aug 2022 | 1 | 2.6% | -23.6% | +25.2% |
| Feb 2023 | Mar 2026 | 158 | 59.5% | -15.6% | +19.2% |
| Average | 55 | — | +7.9% | — |
Frequently Asked Questions
Is DAWN below its 200-week moving average?
No. Day One Biopharmaceuticals, Inc. (DAWN) is currently 58.0% above its 200-week moving average of $13.57. It would need to fall to $13.57 to cross below the line.
What is DAWN's 200-week moving average price?
Day One Biopharmaceuticals, Inc.'s 200-week moving average is $13.57 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when DAWN drops below its 200-week moving average?
DAWN has crossed below its 200-week moving average 3 times in our data. On average, buying at that moment produced a one-year return of +7.9%. These dips have historically been decent entry points. These episodes lasted 55 weeks on average.
Is DAWN a good value right now?
Here's what our data says about DAWN as of 2026-03-20: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 86 (overbought). Free cash flow is currently negative. Return on equity is -22.7%. Price-to-book is 5.0x. This is not a buy or sell recommendation — always do your own research.
How does DAWN compare to the S&P 500?
Over the past 3.9 years, $100 invested in DAWN would have grown to $305, compared to $166 for the S&P 500. That's 33.0% annualized vs 13.8% for the index. DAWN has outperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20